NCT04275583View on ClinicalTrials.gov

A Study to Evaluate the Tolerance and Pharmacokinetics of TQB3602 Capsule

PHASE1UnknownINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

May 28, 2020

Primary Completion Date

December 30, 2022

Study Completion Date

December 30, 2022

Conditions
Multiple Myeloma
Interventions
DRUG

TQB3602

This is a kind of proteasome inhibitor.

Trial Locations (1)

610000

RECRUITING

West China hospital, Sichuan University, Chengdu

Sponsors
All Listed Sponsors
lead

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

INDUSTRY